This systematic evidence-based review by the American Society for Blood and Marrow Transplantation (ASBMT) evaluated the role of hematopoietic cell transplantation (HCT) in the treatment of multiple myeloma. The report discusses the decision to proceed with autologous HCT, factors to consider before proceeding to HCT, the role of tandem autologous HCT, post-HCT maintenance therapy, and the role of allogeneic HCT for patients with multiple myeloma. In this period of rapid changes in the management of myeloma, recommendations were unanimously agreed upon by a panel of multiple myeloma experts. Results from current clinical trials, including BMT CTN 0702 and 1304, are anticipated to further clarify the role and timing of HCT.
ASBMT Evidence-Based Review: The Role of HCT in Multiple Myeloma